WO2000074716A3 - Ige peptides for allergy immunotherapy - Google Patents

Ige peptides for allergy immunotherapy Download PDF

Info

Publication number
WO2000074716A3
WO2000074716A3 PCT/EP2000/005164 EP0005164W WO0074716A3 WO 2000074716 A3 WO2000074716 A3 WO 2000074716A3 EP 0005164 W EP0005164 W EP 0005164W WO 0074716 A3 WO0074716 A3 WO 0074716A3
Authority
WO
WIPO (PCT)
Prior art keywords
allergy
ige
composition
treatment
immune response
Prior art date
Application number
PCT/EP2000/005164
Other languages
French (fr)
Other versions
WO2000074716A2 (en
Inventor
Jean-Paul Prieels
Original Assignee
Smithkline Beecham Biolog
Prieels Jean Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Prieels Jean Paul filed Critical Smithkline Beecham Biolog
Priority to AU58116/00A priority Critical patent/AU5811600A/en
Publication of WO2000074716A2 publication Critical patent/WO2000074716A2/en
Publication of WO2000074716A3 publication Critical patent/WO2000074716A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a composition for the prophylaxis or treatment of allergy. The composition comprises a plurality of allergy peptides linked together by an inert carrier; characterised in that said allergy peptides are derived from IgE or IgE receptor, and that the inert carrier does not contain a peptidic T-cell helper epitope which is capable of binding to an MHC molecule and is capable of stimulating T-cell proliferation, and in a preferred embodiment the carrier does not provide bystander T-cell cytokine help in the induction of the anti-peptide immune response. Also provided are methods of their manufacture and their use in medicine. There is also provided a method of treatment of allergy comprising priming the immune system with an IgE peptide/protein conjugate, followed by boosting the immune response with a composition of the present invention.
PCT/EP2000/005164 1999-06-08 2000-06-06 Ige peptides for allergy immunotherapy WO2000074716A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58116/00A AU5811600A (en) 1999-06-08 2000-06-06 Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913327.4A GB9913327D0 (en) 1999-06-08 1999-06-08 Vaccine
GB9913327.4 1999-06-08

Publications (2)

Publication Number Publication Date
WO2000074716A2 WO2000074716A2 (en) 2000-12-14
WO2000074716A3 true WO2000074716A3 (en) 2001-07-19

Family

ID=10854961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005164 WO2000074716A2 (en) 1999-06-08 2000-06-06 Ige peptides for allergy immunotherapy

Country Status (3)

Country Link
AU (1) AU5811600A (en)
GB (1) GB9913327D0 (en)
WO (1) WO2000074716A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849260B2 (en) 2000-08-18 2005-02-01 Amgen Inc. Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
CN102702359A (en) * 2004-02-02 2012-10-03 泰勒公司 Identification of novel igE epitopes
EP1930729A1 (en) * 2006-12-04 2008-06-11 Medizinische Universität Wien Method for in vivo and in vitro testing for a pharmaceutical drug induced immediate type hypersensitivity reactions
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261973A (en) * 1976-08-17 1981-04-14 Pharmacia Ab Allergen-containing substances
WO1995026365A1 (en) * 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
WO2000050460A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261973A (en) * 1976-08-17 1981-04-14 Pharmacia Ab Allergen-containing substances
WO1995026365A1 (en) * 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
WO2000050460A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.R. STANWORTH ET AL.: "Allergy treatment with a peptide vaccine.", THE LANCER, vol. 336, 24 November 1990 (1990-11-24), LONDON, GB, pages 1279 - 1281, XP002157626 *

Also Published As

Publication number Publication date
WO2000074716A2 (en) 2000-12-14
AU5811600A (en) 2000-12-28
GB9913327D0 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
CA2290485A1 (en) Method for the production of non-immunogenic proteins
AU2002347369A8 (en) Immunotherapeutic methods and systems
ATE244891T1 (en) METHOD FOR SELECTION AND PRODUCTION OF T-CELL PEPTIDES EPITOPES AND VACCINES WITH THESE EPITOPES
HUP0301789A2 (en) Recombinant anti-cd40 antibody and uses thereof
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
DK1098910T3 (en) Antigen Complex Containing Immune Stimulating Peptide, CD4 and Chemokine Receptor Domain for the Treatment of HIV and Immune Diseases
CA2243559A1 (en) Pharmaceutical composition for immunomodulation
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
McCabe et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses
WO2000075173A3 (en) Peptide fragments of colostrinin
Ahmad et al. DNA vaccination for prostate cancer, from preclinical to clinical trials-where we stand?
ATE524192T1 (en) PEPTIDE SUITABLE FOR IMMUNE MODULATION
WO2000074716A3 (en) Ige peptides for allergy immunotherapy
UA83989C2 (en) Isolated peptide for promoting anti-tumor immune response, pharmaceutical composition based thereon and use thereof
CA2440610A1 (en) Induction of tumor immunity by variants of folate binding protein
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
Schappert et al. Soluble MHC class I complexes for targeted immunotherapy
AU2003217758A1 (en) Cytokines and cytokine receptors with reduced immunogenicity
WO2002044202A3 (en) Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
AU5872594A (en) Vaccination with peptide of mhc class ii molecules for treatment of autoimmune disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP